fashion -WSS

fashion

author：explore 2025-09-02 08:14:57 - browse：7318

Adderall XR capsules are displayed on Feb. 24, 2023. Drug shortages are growing in the United States, and experts see no clear path to resolving them. – health care policy coverage from STAT — Medicare has a new proposal to pay hospitals more to stockpile essential drugs, an effort to avoid shortages of chemotherapies and other drugs. Jenny Kane/AP

WASHINGTON — Medicare has a new proposal to pay hospitals more to stockpile essential drugs — an idea that comes as doctors report running low on critical chemotherapies and other drugs. But experts caution the policy could cause the very shortages that government officials are trying to avoid.

For years most of the solutions for addressing drug shortages have involved giving the Food and Drug Administration more power. During the Covid-19 pandemic, Congress empowered the FDA to make drug companies create backup plans for manufacturing facility interruptions, and to collect information from drug makers on where they source ingredients. The FDA also has the authority to prioritize reviews of applications for drugs in short supply and to prioritize inspections of manufacturing facilities that plan to ramp up production.

But Medicare has its own new idea: paying hospitals to create a “buffer stock” of 86 medicines that HHS deems critical. Medicare would not pay hospitals for the drugs. Rather, it would pay hospitals for the cost of managing a three-month inventory of the drugs. It published the proposal in a rule last week; it’s seeking comment now before it will weigh whether to finalize the policy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Donald Trump's relentless attacks on special counsel Jack Smith

leisure time

WSS

Gene therapy has helped boys walk. Can scientists keep it that way?

Why drug prescriptions should include diagnoses

Health insurers' Q3 question: how much care are people getting?

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

The Karikó problem: Lessons for funding basic research

3 hurdles to bringing medical devices to the U.S. market

Wikipedia

fashion

explore

In age of alternative facts, a scholarly course on calling out crap

Weight bias in eating disorder treatment complicated by new weight loss drugs

Walensky prepares to leave CDC — and Congress — behind

The stability of $0 premiums in Medicare Advantage

FDA approval of Sarepta Duchenne genetic therapy gives me hope

3 hurdles to bringing medical devices to the U.S. market

At least 13 dead in Texas as scorching temps continue

Do masks work? RCTs can't tell us

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Death of patient in Alzheimer’s trial raises question of possible risks

entertainment

Stop Congress from blocking public access to science

The battle over the Brookhaven Landfill on Long Island

STAT's guide to the next generation of CAR

Why drug prescriptions should include diagnoses

Setback for rare diseases as Taysha Gene Therapies pulls back

Death of patient in Alzheimer’s trial raises question of possible risks

knowledge

leisure time

hotspot

Wikipedia